148933-92-0

Basic information

• Product Name: <1S-<1α(3R*,5S*),2α,6β,8β,8aα>>-1<<(1,1-Dimethyethyl)diphenylsilyl>oxy>-7-(1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthalenyl)-3,5-heptanediol
• Synonyms: <1S-<1α(3R*,5S*),2α,6β,8β,8aα>>-1<<(1,1-Dimethyethyl)diphenylsilyl>oxy>-7-(1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthalenyl)-3,5-heptanediol
• CAS NO: 148933-92-0
• Molecular Weight: 562.865
• Mol File: 148933-92-0.mol

Chemical Properties

• CAS DataBase Reference: <1S-<1α(3R*,5S*),2α,6β,8β,8aα>>-1<<(1,1-Dimethyethyl)diphenylsilyl>oxy>-7-(1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthalenyl)-3,5-heptanediol(CAS DataBase Reference)
• NIST Chemistry Reference: <1S-<1α(3R*,5S*),2α,6β,8β,8aα>>-1<<(1,1-Dimethyethyl)diphenylsilyl>oxy>-7-(1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthalenyl)-3,5-heptanediol(148933-92-0)
• EPA Substance Registry System: <1S-<1α(3R*,5S*),2α,6β,8β,8aα>>-1<<(1,1-Dimethyethyl)diphenylsilyl>oxy>-7-(1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthalenyl)-3,5-heptanediol(148933-92-0)

Safety Data

• Hazardous Substances Data: 148933-92-0(Hazardous Substances Data)

Upstream product

• 148969-22-6 <1S-<1α(3R*,5S*),2α,6β,8β,8aα>>-7-(1,2,6,7,8,8a-Hexahydro-8-hydroxy-2,6-dimethyl-1-naphthalenyl)-1,3,5-heptanetriol 
• 58479-61-1 tert-butylchlorodiphenylsilane 
• 75330-75-5 lovastatin 

Downstream Products

• 116996-45-3 <1S-<1α,3α,7β,8β(4S^*,6R^*),8aβ>>-8-<2-<6-<2-<<(1,1-dimethylethyl)diphenylsilyl>oxy>ethyl>-2,2-dimethyl-1,3-dioxan-4-yl>ethyl>-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-1-naphthalenol 
• 116996-32-8 <4R-<4α(4R^*,5R^*),6α>>-5-<2-<6-<2-<<(1,1-dimethylethyl)diphenylsilyl>oxy>ethyl>-2,2-dimethyl-1,3-dioxan-4-yl>ethyl>-4-methyl-2-cyclohexen-1-one 
• 148933-93-1 <1aR-<1aα,2β,4β,4aα,5α(4R*,6S*),6α>>-5-<2-<6-<2-<<(1,1-Dimethylethyl)diphenylsilyl>oxy>ethyl>-2,2-dimethyl-1,3-dioxan-4-yl>ethyl>-1a,2,4,4a,5,6-hexahydro-2,6-dimethyl-3H-naphth<1,8a-b>oxiren-4-ol 
• 161466-49-5 (3R,7S,8S,8aR)-8-(2-{(4R,6S)-6-[2-(tert-Butyl-diphenyl-silanyloxy)-ethyl]-2,2-dimethyl-[1,3]dioxan-4-yl}-ethyl)-3,7-dimethyl-3,7,8,8a-tetrahydro-2H-naphthalen-1-one 
• 161466-52-0 (2S,3S,7S,8S,8aR)-8-(2-{(4R,6S)-6-[2-(tert-Butyl-diphenyl-silanyloxy)-ethyl]-2,2-dimethyl-[1,3]dioxan-4-yl}-ethyl)-2-hydroxy-3,7-dimethyl-3,7,8,8a-tetrahydro-2H-naphthalen-1-one 
• 1026249-35-3 (1R,5S,6S)-6-(2-{(4R,6S)-6-[2-(tert-Butyl-diphenyl-silanyloxy)-ethyl]-2,2-dimethyl-[1,3]dioxan-4-yl}-ethyl)-5-methyl-2-[(S)-2-methyl-3-oxo-prop-(Z)-ylidene]-cyclohex-3-enecarboxylic acid methyl ester 
• 161466-50-8 (4S,6R)-4-[2-(tert-Butyl-diphenyl-silanyloxy)-ethyl]-6-[2-((1S,2S,6S,8aR)-2,6-dimethyl-8-triethylsilanyloxy-1,2,6,8a-tetrahydro-naphthalen-1-yl)-ethyl]-2,2-dimethyl-[1,3]dioxane 

Relevant articles and documents

Studies on the Degradation of Mevinolin and Compactin: A Formal Route to Semisynthetic Analogues

Procedures are described for degrading mevinolin (1a) and compactin (1b) into the enone 2, which is a substance that has been elaborated into 1a, 1b, and 3-ethylcompactin (1c).Consequently, 2 serves as an advanced intermediate for the construction of semi

Formal Preparation of Semisynthetic Analogues of the Cholesterol-lowering Agent Mevinolin

The cholesterol-lowering agent mevinolin 1 has been degraded to the enone 4, which had previously been synthesized and converted into mevinolin 1, compactin 2 and 3-ethylcompactin 3.